Drug firm Aurobindo Pharma has received final approval from USFDA to manufacture and market Rivastigmine Tartrate Capsules USP, used for the treatment of dementia disease, in the American market.

• The approved product is bioequivalent and therapeutically equivalent to Novartis Pharmaceuticals Corporation’s Exelon Capsules.
• The approved product has an estimated market size of USD 26.7 million for the twelve months ending January 2016.
• Exelon is used in the treatment of mild moderate dementia of the Alzheimer’s and Parkinson’s disease.

What is Dementia?

• Dementia is a general term for a decline in mental ability severe enough to interfere with daily life. Memory loss is an example. Alzheimer’s is the most common type of dementia.
• Dementia is not a specific disease. It’s an overall term that describes a wide range of symptoms associated with a decline in memory or other thinking skills severe enough to reduce a person’s ability to perform everyday activities.
• Dementia is often incorrectly referred to as “senility” or “senile dementia,” which reflects the formerly widespread but incorrect belief that serious mental decline is a normal part of aging.
• People with dementia may have problems with short-term memory, keeping track of a purse or wallet, paying bills, planning and preparing meals, remembering appointments or traveling out of the neighborhood.